[go: up one dir, main page]

BR9812650A - nucleic acids hybridizing multiple labeling, preparation of the same, compositions, formulation, kits and applications - Google Patents

nucleic acids hybridizing multiple labeling, preparation of the same, compositions, formulation, kits and applications

Info

Publication number
BR9812650A
BR9812650A BR9812650-4A BR9812650A BR9812650A BR 9812650 A BR9812650 A BR 9812650A BR 9812650 A BR9812650 A BR 9812650A BR 9812650 A BR9812650 A BR 9812650A
Authority
BR
Brazil
Prior art keywords
kits
formulation
compositions
applications
preparation
Prior art date
Application number
BR9812650-4A
Other languages
Portuguese (pt)
Inventor
Jonathan W Nyce
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/093,972 external-priority patent/US6825174B2/en
Application filed by Univ East Carolina filed Critical Univ East Carolina
Publication of BR9812650A publication Critical patent/BR9812650A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção: <B>"áCIDOS NUCLEìCOS HIBRIDIZANDO MARCAçãO MúLTIPLA, PREPARAçãO DOS MESMOS, COMPOSIçõES, FORMULAçãO, KITS E APLICAçõES"<D>. Oligonucleotídeos anti-sentido que ligam a duas ou mais marcações de RNA são descritos.Invention Patent: <B> "NUCLEIC ACIDS HYBRIDIZING MULTIPLE MARKING, PREPARATION OF THE SAME, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS" <D>. Antisense oligonucleotides that bind to two or more RNA tags are described.

BR9812650-4A 1997-09-17 1998-09-17 nucleic acids hybridizing multiple labeling, preparation of the same, compositions, formulation, kits and applications BR9812650A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5916097P 1997-09-17 1997-09-17
US09/093,972 US6825174B2 (en) 1995-06-07 1998-06-09 Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
PCT/US1998/019419 WO1999013886A1 (en) 1997-09-17 1998-09-17 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Publications (1)

Publication Number Publication Date
BR9812650A true BR9812650A (en) 2000-08-22

Family

ID=26738426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812650-4A BR9812650A (en) 1997-09-17 1998-09-17 nucleic acids hybridizing multiple labeling, preparation of the same, compositions, formulation, kits and applications

Country Status (8)

Country Link
EP (1) EP1019065A4 (en)
JP (1) JP2003517428A (en)
KR (1) KR20010030622A (en)
AU (1) AU752531B2 (en)
BR (1) BR9812650A (en)
CA (1) CA2304312A1 (en)
IL (1) IL135140A0 (en)
WO (1) WO1999013886A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US20040043948A1 (en) * 2001-09-24 2004-03-04 Isis Pharmaceuticals Inc. Antisense modulation of interleukin 8 expression
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) * 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030060438A1 (en) * 2000-08-18 2003-03-27 Henry James L. Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003268032A1 (en) * 2002-07-29 2004-02-16 Epigenesis Pharmaceuticals, Inc. Composition and methods for treatment and screening
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2004035759A2 (en) * 2002-10-18 2004-04-29 Genta Salus Llc Inhibitory oligonucleotides targeted to matrix metalloproteinase-9
WO2004043353A2 (en) * 2002-11-06 2004-05-27 Ludwig Institute For Cancer Research Compositions and methods for treating acute myeloid leukemia
CA2421086A1 (en) * 2003-02-28 2004-08-28 Institut Pasteur Chicken rna polymerase i promoter and its use
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
AU2005299218B2 (en) 2004-10-29 2012-04-12 Pharmaxis Ltd Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
EP1859040A2 (en) * 2005-02-25 2007-11-28 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
CN102712925B (en) * 2009-07-24 2017-10-27 库尔纳公司 Treatment of SIRTUIN (SIRT)-associated diseases by inhibiting the natural antisense transcript of SIRTUIN (SIRT)
ES2663009T3 (en) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibition of RNA-mediated gene expression using short interference nucleic acids (ANic)
WO2015130832A1 (en) * 2014-02-25 2015-09-03 The Regents Of The University Of California Agents for enhancement of production of biofuel precursors in microalgae
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US10350307B2 (en) * 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
TW202023574A (en) 2018-08-13 2020-07-01 美商阿尼拉製藥公司 Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
AU2020271894A1 (en) 2019-04-11 2021-12-02 Enclear Therapies, Inc. Methods of amelioration of cerebrospinal fluid and devices and systems therefor
CN110527630B (en) * 2019-05-24 2021-04-20 浙江工业大学 Aleurites lutescens mutant strain bred by ARTP mutagenesis technology and application thereof
EP4087929A4 (en) * 2020-01-08 2024-03-20 Microvascular Therapeutics LLC Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery
CA3197180A1 (en) 2020-09-29 2022-04-07 Enclear Therapies, Inc. Subarachnoid fluid management method and system
AU2022297513A1 (en) * 2021-06-23 2024-01-18 Enclear Therapies, Inc. Method of regulating gene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210273D0 (en) * 1992-05-13 1992-07-01 Ici Plc Dna
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease

Also Published As

Publication number Publication date
CA2304312A1 (en) 1999-03-25
EP1019065A1 (en) 2000-07-19
JP2003517428A (en) 2003-05-27
AU752531B2 (en) 2002-09-19
KR20010030622A (en) 2001-04-16
AU9395198A (en) 1999-04-05
EP1019065A4 (en) 2002-02-20
IL135140A0 (en) 2001-05-20
WO1999013886A1 (en) 1999-03-25
WO1999013886B1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
BR9812650A (en) nucleic acids hybridizing multiple labeling, preparation of the same, compositions, formulation, kits and applications
BR9813264A (en) fatty acids, surfactant systems and consumer products based on them
FR2715847B1 (en) Composition containing nucleic acids, preparation and uses.
ATE225369T1 (en) DOUBLE STRANDED PEPTIDENUCLIC ACIDS
BR0214683A (en) Nucleotide or nucleoside molecule, methods of labeling a nucleic acid molecule and for determining the sequence of a single stranded target polynucleotide;
DE69403642D1 (en) 7-DEAZAPURIN MODIFIED OLIGONUCLEOTIDES
DZ2805A1 (en) Pyrrolo, pyrimidine and pyrimidine compositions and uses thereof
MX9700270A (en) Nucleic acid containing composition, preparation and uses of same.
FI953743L (en) Cosmetic compositions having keratolytic and/or anti-acne activity, their preparation and use
DK1218545T3 (en) Methods of Preparation of Oligonucleotide Solutions
FI973039A7 (en) Novel farnesyltransferase inhibitors, their preparation and pharmaceutical compositions containing them
EP0711814A3 (en) Fluorescent marking composition and fluorescent mark formed by this composition
FI954699L (en) MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, their nucleic acid components and their applications
DE69609725D1 (en) NEW POLYMER CARRIER FOR NUCLEIC ACID SYNTHESIS
BR9804918B1 (en) process of identifying the mechanism of resistance of a microorganism to antimicrobial agents.
DE69828080D1 (en) PYRIMIDINE DERIVATIVES AS MARKED BINDING PARTNERS
BR9815443A (en) Alkaline liquid compositions for hard surface cleaning comprising n-vinylpyrrolidone copolymer
EE04398B1 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol, process for their preparation and use as pharmaceuticals
EP0939130A4 (en) POLYMERASE RNA
DE69501081D1 (en) OLIGONUCLEOTIDES WITH ANTI-CYTOMEGALOVIRUS EFFECT
BR9814188A (en) &#34;5-ht1f agonists&#34;
BR9910787A (en) Useful methods and compositions for modulating deangiogenesis using tyrosine kinase src
BR9801143A (en) Innovative siloxane block copolymers with rigid spacing and use.
BR9813897A (en) Biphenyl derivatives as pharmacists
WO2000004141A3 (en) Use of nucleic acid molecules as antiviral agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.